ArticleMicrobial cell factories2025
Multiplex metabolic engineering of yeast for high-efficiency all-trans-retinoic acid production.
Article in Microbial cell factories, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolic Engineering of Komagataella Phaffii for de Novo Synthesis of Retinol From Methanol.Biotechnology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAll-trans-retinoic acid (ATRA) is a pivotal signaling molecule with multifaceted roles in cellular regulation and has broad valuable applications in pharmacology and dermatology. The demand for ATRA is growing, but there is a significant gap in research on its effective biosynthesis.
resultsIn this study, a β-carotene-producing chassis strain was firstly constructed by mining optimal Crt gene combinations, changing platform strains and adjusting the Crt gene copy numbers. Then, the optimal gene combination of the ATRA module was screened, and the subcellular locations of the enzymes were identified. To boost the expression of ER-localized proteins in the ATRA pathway, INO2 was employed to expand the size of the endoplasmic reticulum. Furthermore, sthA was introduced to improve the cellular NADPH and NAD+ levels to meet the high demand for redox cofactors. The supply of oxygen was increased by inserting the Vitreoscilla hemoglobin gene (VHb). In addition, acetyl-CoA was enhanced by overexpressing IME4 and the ATRA biosynthesis module was further strengthened. Finally, the autotrophic markers were complemented and the ATRA titer reached 1.84 g/L in a 5-L bioreactor.
conclusionThis synthetic biology platform can serve as a basis for creating an industrial microbial source of ATRA and other vitamin A derivates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.